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more, murine vSMCs that lack this receptor exhibit a decreased collagen
production and cross-linking,whereas collagenases are increased, accom-
panied by decreased collagen content in atherosclerotic lesions in hyper-
lipidemic mice lacking FPR2/ALX [5].
Importantly, lipoxins are produced during percutaneous coronary
interventions (PCI), and their levels increase after aspirin treatment
[6]. However, the role of ATL signaling through the FPR2/ALX receptor
in vSMC and vascular injury has remained unexplored. Therefore, the
aim of the present study was to explore the ATL signaling through
FPR2/ALX in vSMCs in vitro and in a mouse model of carotid artery liga-The beneﬁt of aspirin is well established in cardiovascular preven-
tion, and involves the irreversible inhibition of platelet cyclooxygenase
(COX)-1 and, as a consequence, decreased thromboxane levels [1]. In
addition to inhibition of platelet aggregation, aspirin may also have
anti-inﬂammatory properties, with potential additional beneﬁt in ath-
erosclerosis prevention. Acetylation of the COX-2 enzyme by aspirin
directs the metabolism of polyunsaturated fatty acids (PUFAs) towards
a biosynthetic pathway, which in addition involves lipoxygenase
enzymes and leads to the formation of speciﬁc mediators, such as 15-
epi-lipoxin A4, also referred to as aspirin-triggered lipoxin (ATL) [2].
ATL has been shown to promote the resolution of inﬂammation [3].
ATL shares its receptor with several other ligands, for example anti-
bacterial peptides such as the cathelicidin LL-37, and this receptor has
therefore been denoted as FPR2/ALX (formyl peptide receptor 2 and A
type lipoxin receptor) [4]. It was recently shown that FPR2/ALX is
expressed in human carotid atherosclerotic lesions, and that higher
expression levels are inversely associated with clinical signs of cerebral
ischemia, suggesting that this receptor may transduce increased athero-
sclerotic plaque stability [5]. In addition to macrophages, the latter study
also identiﬁed vascular smooth muscle cells (vSMCs) in humanenter for Molecular Medicine,
Sweden.
land Ltd. This is an open access articlatherosclerotic lesions expressing the FPR2/ALX receptor [5]. Further-
tion in vivo.
Mice lacking the FPR2/ALX homologue (Fpr2−/−; FPR2/ALX knock-
out [KO] mice) and wild type (Fpr2+/+; WT) mice were generated as
previously described [7]. Aortic vSMCs were isolated from WT and KO
mice, and used for evaluation of proliferation and migration according
to established protocols [1,5,8]. Finally, FPR2/ALX WT and KO mice
were subjected to ligation of the left common carotid artery. Further-
more, based on observations in the present and previous [3] studies
that ATL acts as an inhibitor of vSMC responses in vitro, either ATL
(10 μg/kg) or vehicle (15% ethanol in PBS) was administrated by
means of osmotic pumps following carotid ligation. Experimental de-
tails are given in the Supplementary material. All animal experiments
were performed according to procedures approved by the local ethics
committee.
Vascular SMC derived from FPR2/ALX KO mice exhibited 2.3 ± 0.2
fold higher proliferation compared with wild type vSMCs (P b 0.05;
Fig. 1A). To further extend this observation, vSMC migration was
assessed by a scratch assay, which revealed that ATL (100 nM) reduced
WT vSMCmigration by 26± 3% (P b 0.05). Fig. 1B depicts a representa-
tive experiment of the effects of ATL after 24 h inWT vSMCs. The critical
role of FPR2/ALX in vSMC signalingwas further reinforced by the obser-
vation that FPR2/ALX KO vSMCs exhibited an accelerated migration,
closing 75 ± 9% of initial wound at 24 h, compared with WT 45 ± 6%
closure in vSMCs (P b 0.05; Fig. 1C). Importantly, and in contrast to
the results obtained inWT cells, FPR2/ALX KO cells remained unrespon-
sive to ATL (Fig. 1E). Taken together, these results support a previous
study demonstrating that ATL inhibited PDGF-induced migration ofe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).











Fig. 1. (A) Comparison of vSMC proliferation in vascular smooth muscle cells (vSMCs) derived from either wild type (WT) or FPR2/ALX knock-out (KO) mice. Results (mean ± SEM) are
expressed in ODs and each bar represents quadruplicates of cells derived from 3 different mice of each genotype. *P b 0.05 vsWT. (B) Representative micrographs of the scratch assay at
24 h, showing WT vSMCs in the absence (left panel) and presence (right panel) of aspirin-triggered lipoxin (ATL; 100 nM). (C–E) Time course of vSMC migration in the scratch assay.
Results (mean ± SEM) are expressed as percent closure of initial scratch over a period of 24 h. Four groups were compared; WT in the absence (closed circles) and presence (closed
squares) of ATL (100 nM), and FPR2/ALX KO in the absence (open circles) and presence (open squares) of ATL (100 nM), N=4. *P b 0.05 comparedwith eitherWT (C) or ATL-treated (D).
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to the notion that ATL inhibits vSMC migration through FPR2/ALX re-
ceptor signaling.
Based on these in vitro ﬁndings, a carotid ligationmodel was used to
assess the impact of FPR2/ALX signaling on intimal hyperplasia in vivo.
Administration of ATL reduced the intima area and intima/media ratio
4 weeks after carotid ligation in WT mice (Fig. 2), supporting previous
studies of D-series resolvins [9] and the murine homologue of LL-37
[10]. Interestingly, ATL failed to induce any signiﬁcant effects when ad-
ministered to KOmice (Fig. 2). The latter results for the ﬁrst time pointFig. 2. (A) Effects of ATL (10 μg/kg) on the development of intima hyperplasia 28 days after car
mice in vivo. In each graph, the intimal hyperplasia was quantiﬁed every 100 μm from carotid b
(right panels).WTmice treatedwith either vehicle (N=9, closed circles) or ATL (N=7, closed
squares). Each point represents by mean ± SEM, *P b 0.05 vs. Vehicle. (B) Representative microut a crucial role of ATL-signaling through FPR2/ALX in the response to
vascular injury.
In summary, two major observations emerge from the present
study. First, ATL induced effective inhibition of vSMCmigration and con-
ferred protection against intimal hyperplasia following carotid ligation.
Second, these effects of ATL were transduced through the receptor
FPR2/ALX, as shown by the lack of effect of this ligand in FPR2/ALX KO
mice, both in vitro and in vivo. In addition, an increased proliferation
and faster wound closure were observed in FPR2/ALX KO vSMCs com-
pared with WT cells. In conclusion, these ﬁndings, together with theotid ligation in wilt type (WT; upper panels) and FPR2/ALX knock-out (KO; lower panels)
ifurcation/ligation, and expressed as either intima area (left panels) or intima/media ratio
squares), and KOmice treatedwith either vehicle (N=9, open circles) or ATL (N=8, open
ographs at the 300 μm level from the carotid ligation.
372 M.H. Petri et al. / International Journal of Cardiology 179 (2015) 370–372recently described effects on extracellular matrix deposition and
maturation [5], indicate a potential therapeutic implication of ATL and
FPR2/ALX vSMC signaling in vascular diseases. The pertinence of the ob-
servations for human pathology is further reinforced by the expression
of FPR2/ALX in atherosclerotic lesions [5] and the increasedATL produc-
tion during PCI [6], and provides support for additional beneﬁt of aspirin
in interventional cardiology, which goes beyond platelet inhibition.
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